Compared with the use of other migraine medications, use of erenumab did not increase cardiovascular or cerebrovascular risks.
News-Medical.Net on MSN1d
New trial shows oral semaglutide reduces cardiovascular events in diabetes patientsBoth the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention ...
Sportschosun on MSN4d
Presenting the appropriate duration of medication after carotid stenting...Less than half a year is enough to reduce the risk of bleedingA is a graph comparing the occurrence of ischemic stroke and major bleeding (cerebral hemorrhage, intestinal hemorrhage ...
Semaglutide, a diabetes drug, significantly lowers the risk of heart attacks and strokes in people with type 2 diabetes.
HealthDay on MSN12d
Sonolysis Reduces Risk for Periprocedural Cerebrovascular Events During Carotid Endarterectomy"Sonolysis should be used to reduce the risk of periprocedural cerebrovascular events during carotid endarterectomy in all ...
A large clinical trial has shown that oral semaglutide significantly reduces cardiovascular events in people with type 2 ...
Those with a history of endometriosis or polycystic ovary syndrome had a greater risk for C/CVD and its components in nonmalignant gynecological diseases-specific analyses. HealthDay News ...
Survivors of Stevens-Johnson syndrome and toxic epidermal necrolysis have an increased risk of cardiovascular mortality in the year after diagnosis.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback